Repligen (RGEN) Tops Q2 EPS by 9c ; Offers Guidance
Tweet
Share
E-mailGet Alerts RGEN Hot Sheet
Price: $168.53 +0.55%
EPS Growth %: 0.0%
Financial Fact:
Cost of product revenue: 11.24M
Today's EPS Names:
VIVO, BIOX, PMCB, More
EPS Growth %: 0.0%
Financial Fact:
Cost of product revenue: 11.24M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Repligen (NASDAQ: RGEN) reported Q2 EPS of $0.54, $0.09 better than the analyst estimate of $0.45. Revenue for the quarter came in at $204 million versus the consensus estimate of $201.47 million.
Outlook:-
FY 2026 EPS between $2.03-$2.09 vs consensus $2.
For earnings history and earnings-related data on Repligen (RGEN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Casey's General Stores (CASY) Tops Q1 EPS by 69c
- Troubadour Resources plans $950,000 private placement financing
- ServiceTitan, Inc. (TTAN) Misses Q2 EPS by 1c, Offers Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
